orabase has been researched along with Mycoses* in 3 studies
1 trial(s) available for orabase and Mycoses
Article | Year |
---|---|
Safety and tolerability of cinnamaldehyde in orabase for oral candidiasis treatment: phase I clinical trial.
To advance studies on the effect of a new pharmaceutical formulation for the treatment of oral fungal infections, we evaluated the safety and tolerability of orabase ointment containing cinnamaldehyde for use on the oral mucosa.. A clinical trial (phase I) was carried out on 35 individuals with healthy oral mucosa divided into three groups: ointments at 200 µg/mL, n = 12; 300 µg/mL, n = 11; and 400 µg/mL, n = 12. Product safety was assessed using three parameters: (a) clinical evolution as recorded by trained examiners; (b) evolution of the inflammatory process as registered by an exfoliative cytology exam and analyzed by trained pathologists; (c) mucosal swab to count Candida spp. colony-forming units (CFU). These parameters were analyzed both beforehand and at 15 days of treatment.. The three ointment concentrations evaluated did not trigger inflammatory processes. The mycological analyses revealed a reduction of at least 99% in the number of Candida spp. CFU. In the exfoliative cytology analyses, the cells were found to be healthy. Participants reported a pleasant taste, yet 17% reported a slight burning sensation when applying the product.. The ointment is safe and tolerable for use on healthy oral mucosa.. Registration number: RBR-7zwzs3.. The ointment proved to be safe and tolerable for use on oral mucosa, encouraging studies to evaluate its clinical efficacy in patients with oral candidiasis, and contributing to a new therapeutic proposal for the treatment of fungal infections caused by Candida spp. Topics: Acrolein; Antifungal Agents; Candida; Candidiasis, Oral; Carboxymethylcellulose Sodium; Humans; Mycoses; Ointments | 2022 |
2 other study(ies) available for orabase and Mycoses
Article | Year |
---|---|
Dematiaceous Fungal Colonization of the Bandage Contact Lens in a Patient Lost to Follow-up During the COVID-19 Crisis.
We report a rare case of dematiaceous fungus colonization in the therapeutic bandage contact lens (BCL), in an eye with peripheral ulcerative keratitis. Bandage contact lens removal and appropriate treatment resulted in improvement of the visual acuity and prevented the spread of fungus to the underlying ocular structures. Microbiological evaluation of the BCL showed dematiaceous fungal filaments, and the fungus was identified as Bipolaris species. In patients with pigmented plaque-like lesions, with BCL in situ, dematiaceous fungus on the undersurface of the BCL should be kept in mind. Patient education regarding the importance of frequent BCL replacement, proper ocular hygiene, and timely follow-up should be emphasized. Topics: Aged; Antifungal Agents; Ascomycota; Bandages; Betacoronavirus; Carboxymethylcellulose Sodium; Contact Lenses; Corneal Ulcer; Coronavirus Infections; COVID-19; Eye Infections, Fungal; Humans; Lost to Follow-Up; Male; Mycoses; Natamycin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Tomography, Optical Coherence; Visual Acuity | 2020 |
Properties of modified carboxymethyl cellulose and its use as bioactive compound.
The present study deals with synthesizing novel cellulose derivative, from modifying the carboxymethyl cellulose with amino phenylpropanoic acid (CMC-APP). The synthesized CMC-APP was evaluated as biological and anti-cancer active compound. The molecular structures of this active compound were built using the HyperChem program 7.5, together with conventional analysis (nitrogen content, FT-IR, and non-isothermal TGA analysis). Optimizing the CMC/APPA ratio was carried out as preliminary assessment step, via undetected antimicrobial activity measurement. The TEM study showed that, the synthesized cellulose CMC-APP derivative in the nano-scale particle size (range from 12.5 to 89.3nm). Among all the tested microorganisms and MCF-7 breast cancer cells, the synthesized nano-cellulose derivative is possible used as safety medicine for microbial infections and cancers. The minimal inhibitory concentration (MIC) for Gram-positive bacteria, and gram-negative bacteria are 48.82μg/mL and 97μg/mL, respectively. While, the unicellular fungi and filamentous fungi are 12.2μg/mL and 97.65μg/mL, respectively. The cytotoxic index (IC50) for MCF-7 breast cancers is 50μg/mL. Moreover, the computational study of ADMET (absorption, distribution, metabolism, elimination and toxic) properties, of the molecules showed that, this investigated nano-compound is good oral bioavailability. Topics: Amination; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carboxymethylcellulose Sodium; Fungi; Humans; MCF-7 Cells; Models, Molecular; Mycoses; Phenylpropionates | 2016 |